EZH2 and neoplasm: In the same cohort, univariate analysis revealed high EZH2 expression to be associated with poorer overall survival (OS) rates including all tumor entities (EZH2low vs. EZH2high: median OS 2.45 vs. 1.42 years; p = 0.0096) (Figure 1B).